| According to the State Food and Drug | | | | enterprises, small, scattered, random pattern of no |
| Administration's latest statistics, in 2009 received the | | | | real improvement. |
| National New Drug application for registration 3357, | | | | |
| the proportion reached 35% of new drug | | | | Domestically, the impact of drug safety in the |
| applications, the proportion reporting significant | | | | industrial base and social foundation of no |
| increase. This welcome change that our | | | | fundamental change: industry concentration is low, |
| pharmaceutical companies to enhance innovation and | | | | homogeneous competition, competition remains a |
| R & D, drug development is moving from the | | | | serious disorder; a lack of technological innovation and |
| "imitation-based" to "creative imitation combined with" | | | | application, production technology, the overall level of |
| change, medicine, industrial structure is undergoing a | | | | product standards is not enough high; market liquidity |
| strategic adjustment to the sound development of | | | | is not sufficiently standardized, pharmaceutical |
| innovative R & D direction. | | | | market, the lack of fair competition, effective |
| | | | | mechanisms for survival of the fittest; part of the |
| Many investors buy Chinese stocks last year, earning | | | | company's integrity and sense of responsibility is still |
| pours is a proof. Start a new healthcare reform, | | | | weak, and the market in the industrialized production |
| national essential drug system is implemented, a | | | | of large circulation, a large open structure, the illegal |
| surge in flu vaccines and drugs such as amount of | | | | production harm caused by business activities easily |
| good and market demand driven by Chinese shares | | | | multiplied to enlarge. In addition, labor disputes, |
| rise more than 50 doubles only, pharmaceutical index | | | | increased costs, changes in property rights, also as a |
| also hit a new high in November last year, beyond | | | | constraint to the development of pharmaceutical |
| the broader market 6,000 point of valuation. | | | | industry, the reality of health factors. |
| | | | | |
| With the basic medical and health services, essential | | | | From the international point of view, economic |
| drugs and gradually covering urban and rural residents, | | | | globalization and trade liberalization accelerate to the |
| medical and health needs will be substantially | | | | medical industry in China has brought more new |
| increased the total, drug structure and drug supply | | | | challenges. With the opening up expanding, more and |
| channels will be significant changes, pharmaceutical | | | | more Chinese products enter the international |
| industry reform and development, mergers and | | | | market, more and more multinationals to the |
| acquisitions, bigger and stronger will be the trend. | | | | development, production and procurement centers to |
| | | | | China, the domestic pharmaceutical companies faced |
| However, the current high risk of drug safety in | | | | with increasingly fierce competition in the market. |
| China and highlights the characteristics of conflicts | | | | |
| have not fundamentally changed. In 2009 investigated | | | | Proved medical industrial restructuring imperative. |
| the glycolipid capsule and selling fake, illegal trade in | | | | While pharmaceutical companies to promote the |
| major cases such as ephedrine compound, are | | | | powerful combination of innovation and technology to |
| exposed to many of China's pharmaceutical | | | | enhance core competitiveness. |